SEC Company Response from Kiromic Biopharma, Inc. (KRBP) (CIK 0001792581) — Jun 25, 2021
Kiromic Biopharma, Inc. (KRBP) (CIK 0001792581)
Date: June 25, 2021 · CIK: 0001792581 · Accession: 0001104659-21-085826
AI Filing Summary & Sentiment
Letter
Kiromic Biopharma, Inc.
7707 Fannin, Suite 140
Houston, TX 77054
June 25, 2021
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Christine Westbrook
Re: Kiromic Biopharma, Inc. (CIK: 0001792581)
Registration Statement on Form S-1
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Kiromic Biopharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Daylight Time, on Tuesday, June 29, 2021, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
KIROMIC BIOPHARMA, INC.
By: /s/ Maurizio Chiriva Internati
Name: Maurizio Chiriva Internati
Title: Chief Executive Officer
-1-
Show Raw Text
CORRESP
1
filename1.htm
Kiromic Biopharma, Inc.
7707 Fannin, Suite 140
Houston, TX 77054
June 25, 2021
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Christine Westbrook
Re:
Kiromic Biopharma, Inc. (CIK: 0001792581)
Registration Statement on Form S-1
Ladies and Gentlemen:
Pursuant to Rule 461 of the
General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Kiromic Biopharma, Inc. (the
“Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so
that it will become effective at 5:00 p.m., Eastern Daylight Time, on Tuesday, June 29, 2021, or as soon thereafter as possible.
Please notify Jeffrey Fessler
of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the
Registration Statement has been declared effective pursuant to this acceleration request.
KIROMIC BIOPHARMA, INC.
By:
/s/ Maurizio Chiriva Internati
Name:
Maurizio Chiriva Internati
Title:
Chief Executive Officer
-1-